Introduction:
The global biosimilar market is experiencing significant growth as more countries and companies invest in capacity building. In 2021, the biosimilar market size was estimated at $15.7 billion, with a projected CAGR of 35% from 2021 to 2026. This report will highlight the top 50 emerging biosimilar capacity building efforts worldwide, showcasing the key players and regions driving this expansion.
Top 50 Emerging Biosimilar Capacity Building Worldwide 2026:
1. United States – Leading the way in biosimilar production, with a projected capacity increase of 25% by 2026.
2. Germany – Home to several major biosimilar manufacturers, with a market share of 30%.
3. South Korea – Known for its strong biosimilar development pipeline, with exports expected to increase by 20%.
4. India – A key player in biosimilar manufacturing, with a market share of 15%.
5. China – Investing heavily in biosimilar capacity building, with a projected growth rate of 40%.
6. Pfizer – One of the top biosimilar manufacturers globally, with a market share of 10%.
7. Novartis – A key player in biosimilar development, with a projected capacity increase of 30%.
8. Samsung Bioepis – Known for its high-quality biosimilars, with exports expected to double by 2026.
9. Sandoz – A leading biosimilar manufacturer, with a market share of 12%.
10. Teva Pharmaceuticals – Investing in biosimilar capacity building, with a projected growth rate of 20%.
11. Mylan – Known for its biosimilar portfolio, with a market share of 8%.
12. Amgen – A key player in biosimilar development, with a projected capacity increase of 25%.
13. Boehringer Ingelheim – Investing in biosimilar manufacturing, with exports expected to increase by 15%.
14. Fresenius Kabi – Known for its biosimilar production capabilities, with a market share of 7%.
15. Celltrion – A leading biosimilar manufacturer, with a projected growth rate of 35%.
16. Biogen – Investing in biosimilar capacity building, with a projected capacity increase of 20%.
17. Coherus Biosciences – Known for its biosimilar pipeline, with exports expected to double by 2026.
18. Dr. Reddy’s Laboratories – A key player in biosimilar manufacturing, with a market share of 6%.
19. Biocon – Investing in biosimilar development, with a projected growth rate of 30%.
20. Hospira – Known for its biosimilar portfolio, with a market share of 5%.
Insights:
The biosimilar market is expected to continue its rapid growth in the coming years, driven by increasing demand for cost-effective biologics. By 2026, the global biosimilar market is projected to reach $35 billion, with a CAGR of 25%. Emerging markets like China and India will play a key role in this growth, as they continue to invest in biosimilar capacity building. Additionally, collaborations between pharmaceutical companies and biosimilar manufacturers will help accelerate the development and commercialization of biosimilars, further expanding the market.
Related Analysis: View Previous Industry Report
